Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Krahl, A."'
Autor:
Hans-Heinrich Wolf, Verena S. Hoffmann, Vladan Vucinic, Maria Cristina Sauerland, Wolfgang Hiddemann, Wolfgang E. Berdel, Thomas Heinicke, Dietger Niederwieser, Karin Hebenstreit, Georg Maschmeyer, Antje Schulze, Detlev Haehling, Rainer Krahl, Ute Hegenbart, Thomas Büchner, Bernhard J. Woermann, Michael Cross, Alwin Kraemer, Sebastian Scholl, Wolfram Pönisch, Mathias Freund, Markus Pfirrmann, Christian Niederwieser, Utz Krug
Publikováno v:
Blood. 120:128-128
Abstract 128 The treatment of elderly patients (pts) with AML remains challenging. High treatment associated mortality using protocols developed for younger patients and high relapse rates for pts reaching CR are frequent causes of failure, while man
Autor:
Enrica Bach, Rainer Krahl, Sabine Tschiedel, Thomas Büchner, Frank Schüler, Gottfried Doelken, Dietger Niederwieser, Thoralf Lange, Haifa Kathrin Al-Ali, Michael Cross
Publikováno v:
Blood. 118:4904-4904
Abstract 4904 Background: Prognostic molecular markers are expected to be of increasing value in stratifying treatment of patients with AML lacking cytogenetic abnormalities. While specific DNA-level mutations such as those in the FLT-3 or NPM1 genes
Autor:
Nadja Jaekel, Gisa Hoppe, Georg Maschmeyer, Thao Tran, Rainer Krahl, Michael Cross, Christian Junghanss, Dietger Niederwieser, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 114:2642-2642
Abstract 2642 Poster Board II-618 Leukaemogenesis is commonly accompanied by global DNA hypomethylation together with hypermethylation and inactivation of specific regulatory genes. Therapy with methylation inhibitors can reactivate regulatory gene e
Autor:
Cornelia Becker, Wolfram Poenisch, Dietger Niederwieser, Haifa Kathrin Al-Ali, Rainer Krahl, Claudia Nehring, Jeanett Edelmann, Sabine Leiblein, Wolf-Dieter Kortmann, Thoralf Lange
Publikováno v:
Blood. 110:5033-5033
Introduction: Relapse of the malignant disease remains the major challenge after reduced intensity conditioning (RIC) HCT. Here we investigate the outcome of haematological relapse after low dose TBI-based conditioning regimens and the possibility to
Autor:
Ruediger Alt, Michael W. Deininger, Ines Kovacz, Thomas Thielsen, Ralf Burckhardt, Christina Franke, Rainer Krahl, Dietger Niederwieser, Guido Zschau, Haifa Kathrin Al-Ali, Thoralf Lange, Sabine Leiblein
Publikováno v:
Blood. 106:1985-1985
Objectives: Most patients with chronic phase CML attain a complete cytogenetic response (CCR) to imatinib (IM) but BCR-ABL remains detectable by RT-PCR, indicating persistence of residual disease. One small study (Bhatia et al. Blood101(12):4701–7,
Autor:
Thomas Bumm, Marc Mueller, Michael W. Deininger, Thoralf Lange, Sandra Otto, Scarlet Musiol, Rainer Krahl, Christina Franke, Leanthe Grommisch, Haifa Kathrin Al-Ali, Dietger Niederwieser
Publikováno v:
Blood. 104:276-276
Objectives: Patients with CML who achieve molecular remission (MR, defined as a RT-PCR negativity for BCR-ABL transcripts) after myeloablative stem cell transplantation (SCT) have a low risk of relapse, and the majority may be cured. The frequency of